GeneDx Holdings Corp. (WGS)Healthcare | Diagnostics & Research | Stamford, United States | NasdaqGS
68.90 USD
-0.81
(-1.162%) ⇩
(April 21, 2026, 10:53 a.m.
EDT)
Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:42 a.m. EDT
GeneDx (WGS) is technically oversold (down ~22% from 200-day average) with high short interest, but the consensus remains a 'Strong Buy' based on the gap between the current $66 price and the $143+ EPS-adjusted target. The stock is fundamentally transitioning from losses to profitability (2026 outlook), but the short-term chart looks volatile and tailored for a potential bottom-fish entry before a multi-year recovery, rather than an immediate momentum breakout. The lack of dividends and bifurcation between short and long-term options flow confirms this is a volatile turnaround play. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.162327 |
| AutoETS | 0.217359 |
| AutoTheta | 0.296715 |
| AutoARIMA | 0.374778 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 39.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.207 |
| Excess Kurtosis | -1.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 36.721 |
| Revenue per Share | 14.927 |
| Market Cap | 2,017,994,240 |
| Forward P/E | 33.49 |
| Beta | 2.19 |
| Profit Margins | -4.92% |
| Website | https://www.genedx.com |
As of April 19, 2026, 12:42 a.m. EDT: Options flow shows aggressive bearish positioning in the very short term (April/May), with massive volume in OTM puts (>258 contracts at $50 strike expiring May 8) and high IV relative to calls at these strikes. However, there is a notable 'long fade' or hedging activity for nearer-dated calls, showing low OTM OI (97% sold for Apr 24, 80% sold for May 1). Long-term calls show higher OI concentration at $80-$85 strikes, while puts show a significant buildup of OI at $75. Speculators are heavily short-term hedging or betting on a drop near the May 4 earnings date, but establishing defense/limits to downside if the stock holds support around $65.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.2805243 |
| Address1 | North Tower |
| Address2 | 6th Floor 333 Ludlow Street |
| All Time High | 896.94 |
| All Time Low | 1.16 |
| Ask | 88.58 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 661,740 |
| Average Daily Volume3 Month | 747,344 |
| Average Volume | 747,344 |
| Average Volume10Days | 661,740 |
| Beta | 2.191 |
| Bid | 52.76 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 10.538 |
| City | Stamford |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 68.9 |
| Current Ratio | 2.463 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 73.46 |
| Day Low | 68.6 |
| Debt To Equity | 36.721 |
| Display Name | GeneDx |
| Earnings Call Timestamp End | 1,777,926,600 |
| Earnings Call Timestamp Start | 1,777,926,600 |
| Earnings Timestamp | 1,777,924,800 |
| Earnings Timestamp End | 1,777,924,800 |
| Earnings Timestamp Start | 1,777,924,800 |
| Ebitda | 12,652,000 |
| Ebitda Margins | 0.029590001 |
| Enterprise To Ebitda | 156.782 |
| Enterprise To Revenue | 4.64 |
| Enterprise Value | 1,983,603,968 |
| Eps Current Year | 0.91167 |
| Eps Forward | 2.05714 |
| Eps Trailing Twelve Months | -0.73 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 201 421 2010 |
| Fifty Day Average | 75.8404 |
| Fifty Day Average Change | -6.940399 |
| Fifty Day Average Change Percent | -0.09151322 |
| Fifty Two Week Change Percent | -28.052431 |
| Fifty Two Week High | 170.87 |
| Fifty Two Week High Change | -101.96999 |
| Fifty Two Week High Change Percent | -0.59676945 |
| Fifty Two Week Low | 55.17 |
| Fifty Two Week Low Change | 13.730003 |
| Fifty Two Week Low Change Percent | 0.24886721 |
| Fifty Two Week Range | 55.17 - 170.87 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,604,500,200,000 |
| Float Shares | 20,848,603 |
| Forward Eps | 2.05714 |
| Forward P E | 33.4931 |
| Free Cashflow | 38,056,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,300 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.69742996 |
| Gross Profits | 298,177,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12562001 |
| Held Percent Institutions | 1.06021 |
| Implied Shares Outstanding | 29,288,739 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,683,158,400 |
| Last Split Factor | 1:33 |
| Long Business Summary | GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut. |
| Long Name | GeneDx Holdings Corp. |
| Market | us_market |
| Market Cap | 2,017,994,240 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_608642327 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -21,021,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,041,717,995 |
| Number Of Analyst Opinions | 9 |
| Open | 70.5 |
| Operating Cashflow | 33,279,000 |
| Operating Margins | -0.10604 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 888 729 1206 |
| Previous Close | 69.71 |
| Price Eps Current Year | 75.57559 |
| Price Hint | 2 |
| Price To Book | 6.538243 |
| Price To Sales Trailing12 Months | 4.7200236 |
| Profit Margins | -0.04917 |
| Quick Ratio | 2.256 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.11111 |
| Region | US |
| Regular Market Change | -0.80999756 |
| Regular Market Change Percent | -1.1618699 |
| Regular Market Day High | 73.46 |
| Regular Market Day Low | 68.6 |
| Regular Market Day Range | 68.6 - 73.46 |
| Regular Market Open | 70.5 |
| Regular Market Previous Close | 69.71 |
| Regular Market Price | 68.9 |
| Regular Market Time | 1,776,783,184 |
| Regular Market Volume | 173,837 |
| Return On Assets | -0.015470001 |
| Return On Equity | -0.07597 |
| Revenue Growth | 0.265 |
| Revenue Per Share | 14.927 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 29,288,739 |
| Shares Percent Shares Out | 0.1346 |
| Shares Short | 3,943,616 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,499,873 |
| Short Name | GeneDx Holdings Corp. |
| Short Percent Of Float | 0.26479998 |
| Short Ratio | 4.95 |
| Source Interval | 15 |
| State | CT |
| Symbol | WGS |
| Target High Price | 177.0 |
| Target Low Price | 90.0 |
| Target Mean Price | 143.88889 |
| Target Median Price | 153.0 |
| Total Cash | 171,282,000 |
| Total Cash Per Share | 5.848 |
| Total Debt | 113,168,000 |
| Total Revenue | 427,539,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.73 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 109.93137 |
| Two Hundred Day Average Change | -41.031372 |
| Two Hundred Day Average Change Percent | -0.37324533 |
| Type Disp | Equity |
| Volume | 173,837 |
| Website | https://www.genedx.com |
| Zip | 6,902 |